Results 211 to 220 of about 113,185 (266)

Analytical performance evaluation and method comparison of the 1copy BCR::ABL1 qPCR assay for monitoring chronic myeloid leukemia. [PDF]

Pract Lab Med
Kim H, Kim DY, Kim H.
europepmc   +1 more source

Chronic Myeloid Leukemia and the T315I <i>BCR::ABL1</i> Mutation. [PDF]

Int J Mol Sci
Pierro F, Stella S, Fazio M, Russo S, Massimino M, Mirabile G, Belletti D, Allegra A, Stagno F.   +8 more
europepmc   +1 more source

Efficacy and safety of high doses of eltrombopag for treating adult immune thrombocytopenia: Results from a multicentre retrospective cohort study

British Journal of Haematology, EarlyView.
Salomé Dahan, Stéphanie Guillet, Olivier Fain, Delphine Gobert, Stéphane Cheze, Florent Broca, Bertrand Godeau, Marc Michel   +7 more
wiley   +1 more source

Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic Opportunities. [PDF]

Cancers (Basel)
Caprino F, Valentino I, Bruzzese A, Ganino L, Mesuraca M, Citraro R, Gentile M, Gallo Cantafio ME, Amodio N.   +8 more
europepmc   +1 more source

Evaluating comorbidity scoring systems for flumatinib therapy in chronic myeloid leukemia: a machine learning and SHAP-based predictive analysis. [PDF]

Front Med (Lausanne)
Yang Y, Li Y, Wang J.
europepmc   +1 more source

Impact of Tyrosine Kinase Inhibitors on Estimated Glomerular Filtration Rate in Chronic Myeloid Leukemia Patients.

Oncology
Alshurafa A, Benkhadra M, Qasem NM, Babiker AM, Al-Asa'd Y, Haik MY, Yassin MA.   +6 more
europepmc   +1 more source

Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.

Blood
Cortes JE, Hughes TP, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Etienne G, Kim I, Andorsky DJ, Bombaci F, Issa GC, Takahashi N, Kapoor S, Jinwal R, Malek K, McCulloch T, Yau L, Larson RA, Hochhaus A.   +20 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Chronic Myeloid Leukemia

New England Journal of Medicine, 1999
Over the past twenty years, clinical and laboratory studies have led to important new insights into the biology of chronic myeloid leukemia. Basic science has defined the molecular pathogenesis of chronic myeloid leukemia (CML) as unregulated signal transduction by the Bcr-Abl tyrosine kinase.
Charles Sawyers, Sawyers Charles L
exaly   +3 more sources

Asciminib in chronic myeloid leukemia

Drugs of Today, 2022
Despite the fact that, in the last years, life expectancy of chronic myeloid leukemia (CML) patients has reached that of the normal population, a significant proportion of CML patients is likely to fail treatment with first- or second-generation tyrosine kinase inhibitors (TKIs).
Assanto, Giovanni Manfredi, Scalzulli, Emilia, Breccia, Massimo   +2 more
openaire   +3 more sources